BRAF and melanoma: Neil Rosen’s group also clearly demonstrated that vemurafenib treatment of BRAF mutant melanoma cells caused receptor tyrosine kinase-mediated (RTK) activation of RAS via Spry2 downregulation, with CRAF activation and pERK rebound after initial profound inhibition [9].